BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 24691993)

  • 1. VISTA is an immune checkpoint molecule for human T cells.
    Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
    Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISTA Regulates the Development of Protective Antitumor Immunity.
    Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
    Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
    Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.
    ElTanbouly MA; Zhao Y; Nowak E; Li J; Schaafsma E; Le Mercier I; Ceeraz S; Lines JL; Peng C; Carriere C; Huang X; Day M; Koehn B; Lee SW; Silva Morales M; Hogquist KA; Jameson SC; Mueller D; Rothstein J; Blazar BR; Cheng C; Noelle RJ
    Science; 2020 Jan; 367(6475):. PubMed ID: 31949051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the immune checkpoint VISTA in breast cancer.
    Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
    Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes.
    Vesely MD; Kidacki M; Gaule P; Gupta S; Chan NNN; Han X; Yeung JT; Chen L
    J Invest Dermatol; 2024 Jan; 144(1):106-115.e4. PubMed ID: 37562584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
    Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
    Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
    Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
    Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
    Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VISTA expressed in tumour cells regulates T cell function.
    Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
    Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.
    He HX; Gao Y; Fu JC; Zhou QH; Wang XX; Bai B; Li PF; Huang C; Rong QX; Ping LQ; He YX; Mao JY; Chen X; Huang HQ
    Oncoimmunology; 2021 Apr; 10(1):1907059. PubMed ID: 33889438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
    Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
    Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
    Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
    J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.